Why This Matters for Your Career
Novartis is hiring 10 roles related to this product
EVEROLIMUS (everolimus) by Novartis is protein kinase inhibitors [moa]. Approved for older with tsc, postmenopausal women with advanced hormone receptor-positive, her2-negative breast cancer in combination with exemestane and 14 more indications. First approved in 2021.
Protein Kinase Inhibitors
Kinase Inhibitor
Worked on EVEROLIMUS at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
REsorbable SCaffolds With everolimUs-Elution for the Treatment of Infrapopliteal Artery Disease in Patients With Chronic Limb-threatening Ischemia
To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System
Optimize Immunosuppressive Therapy Using Everolimus and Low-dose Calcineurin Inhibitors in Heart Transplant Patients in Korea
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
Novartis is hiring 10 roles related to this product